Abstract
What is known and objective: The second-generation direct-acting antivirals represented the first major turning point for the eradication of HCV infection in almost all settings of patients. However, no data were available on use in gastro-resected patients. Case description: We report on a gastrectomized patient with chronic hepatitis C infection. She was treated with sofosbuvir and ledipasvir (SOF/LDV) for 12 weeks, with measurement of blood levels of the drugs. She obtained sustained virological response at week 12 and 24 without dose adjustment. What is new and conclusion: This case report can provide information useful for clinical practice in this set of patients and can open new perspectives in evaluating actual SOF/LDV bioavailability.
| Original language | English |
|---|---|
| Pages (from-to) | 621-623 |
| Number of pages | 3 |
| Journal | Journal of Clinical Pharmacy and Therapeutics |
| Volume | 42 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - Oct 1 2017 |
Fingerprint
Keywords
- gastrectomy
- hepatitis C virus
- ledipasvir
- pharmacokinetics
- sofosbuvir
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
Cite this
Efficacy of sofosbuvir and ledipasvir in an HCV+ gastro-resected patient. / Taibi, C.; Tempestilli, M.; D'Avolio, A.; Garbuglia, A. R.; De Nicolò, A.; Montalbano, M.; D'Offizi, G.
In: Journal of Clinical Pharmacy and Therapeutics, Vol. 42, No. 5, 01.10.2017, p. 621-623.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Efficacy of sofosbuvir and ledipasvir in an HCV+ gastro-resected patient
AU - Taibi, C.
AU - Tempestilli, M.
AU - D'Avolio, A.
AU - Garbuglia, A. R.
AU - De Nicolò, A.
AU - Montalbano, M.
AU - D'Offizi, G.
PY - 2017/10/1
Y1 - 2017/10/1
N2 - What is known and objective: The second-generation direct-acting antivirals represented the first major turning point for the eradication of HCV infection in almost all settings of patients. However, no data were available on use in gastro-resected patients. Case description: We report on a gastrectomized patient with chronic hepatitis C infection. She was treated with sofosbuvir and ledipasvir (SOF/LDV) for 12 weeks, with measurement of blood levels of the drugs. She obtained sustained virological response at week 12 and 24 without dose adjustment. What is new and conclusion: This case report can provide information useful for clinical practice in this set of patients and can open new perspectives in evaluating actual SOF/LDV bioavailability.
AB - What is known and objective: The second-generation direct-acting antivirals represented the first major turning point for the eradication of HCV infection in almost all settings of patients. However, no data were available on use in gastro-resected patients. Case description: We report on a gastrectomized patient with chronic hepatitis C infection. She was treated with sofosbuvir and ledipasvir (SOF/LDV) for 12 weeks, with measurement of blood levels of the drugs. She obtained sustained virological response at week 12 and 24 without dose adjustment. What is new and conclusion: This case report can provide information useful for clinical practice in this set of patients and can open new perspectives in evaluating actual SOF/LDV bioavailability.
KW - gastrectomy
KW - hepatitis C virus
KW - ledipasvir
KW - pharmacokinetics
KW - sofosbuvir
UR - http://www.scopus.com/inward/record.url?scp=85018367711&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85018367711&partnerID=8YFLogxK
U2 - 10.1111/jcpt.12546
DO - 10.1111/jcpt.12546
M3 - Article
VL - 42
SP - 621
EP - 623
JO - Journal of Clinical Pharmacy and Therapeutics
JF - Journal of Clinical Pharmacy and Therapeutics
SN - 0269-4727
IS - 5
ER -